The dispute began in 2014 and involved an early version of the Neodent Drive CM implant, which was superseded soon afterwards. Nobel Biocare claimed that the version in question infringed two of its patents, but Straumann successfully challenged one of them at the US Patent Trial and Appeal Board. The ruling, which invalidated a patent on a key feature of the NobelActive implant, was recently upheld—despite Nobel Biocare’s subsequent appeal to the US Court of Appeals for the Federal Circuit. Nobel Biocare has now agreed to take no further action regarding the decision and to dismiss its pending court action.

“We are delighted with this outcome” said Dr Andreas Meier, General Counsel of Straumann. “Neodent’s new GM implant range is unchallenged and we are not required to pay any compensation.”

Tags: